Journal
NEW BIOTECHNOLOGY
Volume 32, Issue 6, Pages 673-679Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nbt.2014.11.005
Keywords
-
Funding
- Federal Ministry of Economy, Family and Youth (BMWFJ)
- Federal Ministry of Traffic, Innovation and Technology (bmvit)
- Styrian Business Promotion Agency SFG
- Standortagentur Tirol
- ZIT - Technology Agency of the City of Vienna through the COMET-Funding Program
- Herzfeldersche Familienstiftung
Ask authors/readers for more resources
The market of recombinant proteins as human pharmaceuticals has surpassed annual revenues of more than 150 billion dollars. The marketed proteins are often complex in terms of post-translational modifications and conventional hosts have shown weaknesses in terms of quality of these recombinant proteins. Especially the non-human glycopatterns leading to immunogenicity or shortened in vivo half-life have gained attention over the past decade. Therefore, production cell lines with better or novel characteristics are required and human cell lines seem to be the most genuine and logical choice. Thus, several human cell lines have been used to generate biopharmaceuticals. We here present an overview of such examples and highlight their promise for biopharmaceutical production processes of the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available